UK Biobank Pharma Proteomics Project publishes first results of its pioneering research in proteomics

Olink Proteomics AB

UPPSALA, Sweden, June 21, 2022 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) introduced the publication of a publication describing the primary findings of proteomics analysis carried out by the Biobank’s Pharmaceutical Proteomics Undertaking. of the UK (UKB-PPP). printed on-line for bioRxiv prepress server and is on the market right here.

The research, titled โ€œGenetic regulation of the human plasma proteome in 54,306 UK Biobank individualsused Olinkยฎ Discover 1536 and genome sequencing on 54,306 UK Biobank individuals to gather and analyze protein quantitative trait loci (pQTL) mapping knowledge for 1,463 proteins that recognized 10,248 main genetic associations, from which 85% had not been beforehand reported.

The outcomes of the UKB-PPP publication present an up to date genetic atlas of the plasma proteome and supply the scientific neighborhood with an open entry population-scale proteomics useful resource of unprecedented breadth and depth to assist elucidate the organic mechanisms underlying the discoveries. genetic. Measurement of hundreds of proteins on a inhabitants scale guarantees to enhance our understanding of the underlying mechanisms of illness and thus speed up the event of latest biomarkers and therapeutics. As well as, the research highlights the strengths of Olink’s Discover assay for pQTL detection and subsequent organic discovery, with a excessive proportion, 82% of proteins examined, having cis associations, proof from Olink’s extremely particular assays that measure its predicted proteins.

“The landmark analysis by members of the UKB-PPP is a major first step in harnessing the facility of next-generation proteomics together with genetic data to enhance human well being,” he stated. Jon Heimer, CEO of Olink. “We’re terribly grateful that Olink’s Discover platform will be part of this great journey, and we stay up for the complete dataset that shall be delivered to the scientific neighborhood later this yr.”

The UK Biobank Pharmaceutical Proteomics Undertaking is a collaboration between the UK Biobank and 13 biopharmaceutical firms, and is at present conducting one of many world’s largest scientific research of blood protein biomarkers. The UK Biobank is a large-scale biomedical database and analysis useful resource containing detailed well being and genetic data from half 1,000,000 UK individuals. The database is accessible globally to accredited researchers and scientists conducting important analysis on the most typical and life-threatening ailments. UKB-PPP goals to allow a greater understanding of the biology of the illness and help the event of revolutionary medicine for simpler therapies.

Olink Investor Contact
Jan Medina, C.F.A.
Vice President of Investor Relations and Capital Markets
Cell: +1 617 802 4157
jan.medina@olink.com

Olink Media Contact
Andrea Prander
Company Communications Supervisor
Cell: +46 768 775 275
andrea.prander@olink.com

About Olink
Olink Holding AB (Nasdaq: OLK) is an organization devoted to accelerating proteomics along with the scientific neighborhood, throughout a number of illness areas to allow new discoveries and enhance the lives of sufferers. Olink supplies a platform of services and products which might be deployed throughout main biopharmaceutical firms and main scientific and educational establishments to deepen understanding of human biology in actual time and drive twenty first century healthcare by means of actionable and impactful science. The corporate was based in 2016 and is nicely established in Europe, North America and Asia. Olink is predicated in Uppsala, Sweden. Extra about Olink right here.

Ahead-looking statements
This press launch accommodates forward-looking statements which might be primarily based on administration’s beliefs and assumptions and data at present accessible to administration. All statements on this launch that aren’t statements of historic truth are forward-looking statements, together with statements about our 2022 income outlook, our Exploration outsourcings, our skill to develop, commercialize and acquire market acceptance of our merchandise. and present and deliberate providers, our analysis and improvement efforts, and different issues referring to our enterprise methods, use of capital, outcomes of operations and monetary place, and plans and aims for future operations. In some circumstances, you’ll be able to determine forward-looking statements by the phrases “might”, “will”, “may”, “ought to”, “expects”, “intends”, “plans”, “anticipates”, “believes”, ” estimate”, “predict”, “venture”, “potential”, “proceed”, “ongoing” or the adverse of those phrases or different comparable terminology, though not all forward-looking statements comprise these phrases. These statements contain dangers, uncertainties and different components which will trigger precise outcomes, ranges of exercise, efficiency or achievements to vary materially from data expressed or implied by these forward-looking statements. These dangers, uncertainties and different components are described below the heading “Danger Elements” on our Kind 20-F (Fee File Quantity 001-40277) and elsewhere within the paperwork we periodically file with the Securities and Trade Fee. Values. We warning you that forward-looking statements are primarily based on a mix of info and components at present identified to us and our projections for the long run, about which we can’t be sure. Consequently, forward-looking statements will not be correct. Ahead-looking statements on this press launch symbolize our views as of the date hereof. We undertake no obligation to replace any forward-looking assertion for any cause, besides as required by regulation.

Leave a Comment